Skip to content
MARKETS / NASDAQ / LEGN
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Legend Biotech Corp. LEGN

8 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.0B
▲ 64.0% YoY
$-296.8M
$-128.8M
Growth
USD 1.0B
Revenue, FY2025 · full 8-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.0 · Net income -0.3
0.4B0.8B-0.2B-0.4B20182019202020212022202320242025
Compound annual growth
+106.4%
+68.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +68.8% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−29 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -13.3% · Net -28.8%
-200%-400%20182019202020212022202320242025
ROE
FY2025 · ROE -28.5%
-20%-40%-60%20182019202020212022202320242025

Each USD of equity lost 29 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -128.8
100M200M-200M-400M20182019202020212022202320242025

Total assetsUSD 1.7B
CashUSD 901.9M
Gross debtUSD 319.1M
Net debtUSD -582.8M
Current ratio1.96×

Not available: we don't have the shareholders' equity figure for this period.

The 8-year record
8 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 20252024202320222021202020192018
Revenue $B1.00.60.30.10.10.10.10.0
Operating income $B−0.1−0.3−0.5·····
EBITDA $B········
Income tax $B0.00.0−0.00.0−0.0−0.0−0.00.0
Net income $B−0.3−0.2−0.5−0.4−0.4−0.3−0.1−0.0
Free cash flow $B−0.1−0.2−0.4−0.2−0.2−0.2−0.10.3
EPS, diluted $−0.81−0.48−1.47−1.40−1.43−1.13−0.51−0.01
Dividend / sh $········
Payout %········
ROE %−28.5−15.4−51.9−59.1−59.2−71.1−67.1·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 30 reconciliationsAUDITED

Reconciled in 8 of 19 fiscal years. 59 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsDecember 31
Data on record since2018

Share this section

Download image